{"groups":[{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 70 mg/m\\^2 for initial tolerability study (closed) Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles 6 participants to bendamustine 70 mg/m\\^2/day, days 1 and 2 each cycle Acetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"FG000","title":"Non-Randomized to 70 mg/m2 Bendamustine-Rituximab"},{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 90 mg/m\\^2 for initial tolerability study (closed) Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles Bendamustine: 6 participants to bendamustine 90 mg/m\\^2/day, days 1 and 2 each cycle Acetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated","id":"FG001","title":"Non-randomized to 90 mg/m^2 Bendamustine-Rituximab"},{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 90 mg/m\\^2 Rituximab: 28 participants Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles Bendamustine:28 participants to bendamustine 90 mg/m\\^2/day, days 1 and 2 each cycle, days 1 and 2 each cycle Acetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"FG002","title":"Randomized to 90 mg/m^2 Bendamustine-Rituximab"},{"description":"Treatment Assignment Code 2 (TAC 2) Rituximab + Pentostatin\n\nPentostatin: 28 participants to pentostatin 4 mg/m\\^2 days 1 and 15 of each cycle.\n\nRituximab: Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles\n\nAcetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated.\n\nIntravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"FG003","title":"Randomized to Pentostatin-Rituximab"},{"description":"Treatment Assignment Code 5 (TAC 5) Rituximab + Bendamustine at 90 mg/m\\^2 or Rituxan + Pentostatin After initial tolerability studies are completed. Non-randomize up to 4 total participants to Bendamustine and/or Pentostatin with Rituximab Rituximab 375 mg/m\\^2 on day 1, 15 for 6 x 28-day cycles Bendamustine: 1-4 participants to bendamustine 90 mg/m\\^2/day, days 1 and 2 each cycle Pentostatin 1-4 participants to pentostatin 4 mg/m\\^2 days 1 and 15 of each cycle.\n\nAcetaminophen: Treatment of infusion-related symptoms with acetaminophen is recommended.\n\nDiphenhydramine: Treatment of infusion-related symptoms with diphenhydramine is recommended.\n\nEpinephrine: Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nAntihistamines: Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nCorticosteroids: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.\n\nBronchodilators: Additional treatment with bronchodilators may be indicated. Intravenous (IV) Saline: Additional treatment with intravenous (IV) saline may be indicated.","id":"FG004","title":"Non-randomized to Bendamustine 90mg/m^2 or Pentostatin 4mg/m^2 With Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"Did not receive 6 cycles."}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"28"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"27"},{"groupId":"FG004","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}